CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy

NCT00658437 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Cytavis Biopharma GmbH